Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms
Hämostaseologie · 01.10.2024 · 44 (05) · 386-392
DOI: 10.1055/a-2159-8767 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hämostaseologie, erschienen am 01.10.2024. Verfasst von Kai Wille und 9 weiteren Autor:innen. Beteiligte Einrichtung: University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum,…. Hauptthemen laut MEDLINE: Myeloproliferative Disorders. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Arterial (ATE) and venous (VTE) thromboembolic complications are common causes of morbidity and mortality in BCR-ABL-negative myeloproliferative neoplasms (MPNs). However, there are few studies that include all MPN subtypes and focus on both MPN-associated ATE and VTE. In our single-center retrospective study of 832 MPN patients, a total of 180 first thromboembolic events occurred during a median follow-up of 6.6 years (range: 0–37.6 years), of which 105 were VTE and 75 were ATE. The probability of a vascular event at the end of the follow-up period was 36.2%, and the incidence rate for all first ATE/VTE was 2.43% patient/year. The most frequent VTE localizations were deep vein thrombosis with or without pulmonary embolism (incidence rate: 0.59% patient/year), while strokes were the most frequent ATE with an incidence rate of 0.32% patient/year. When comparing the group of patients with ATE/VTE (n = 180) and the group without such an event (n = 652) using multivariate Cox regression analyses, patients with polycythemia vera (hazard ratio [HR]: 1.660; [95% confidence interval [CI] 1.206, 2.286]) had a significantly higher risk of a thromboembolic event than the other MPN subtypes. In contrast, patients with a CALR mutation had a significantly lower risk of thromboembolism compared with JAK2-mutated MPN patients (HR: 0.346; [95% CI: 0.172, 0.699]). In summary, a high incidence of MPN-associated VTE and ATE was observed in our retrospective study. While PV patients or generally JAK2-mutated MPN patients had a significantly increased risk of such vascular events, this risk was reduced in CALR-mutated MPN patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany.
- Core Facility Statistical Consulting, Helmholtz Zentrum München, Munich, Germany.
- Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany.
Zitieren
APA
Wille, K., Deventer, E., Sadjadian, P., Becker, T., Kolatzki, V., Hünerbein, K., Meixner, R., Jiménez-Muñoz, M., Fuchs, C., & Griesshammer, M. (2024). Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms. Hämostaseologie, 44(05), 386-392. https://doi.org/10.1055/a-2159-8767
Vancouver
Wille K, Deventer E, Sadjadian P, Becker T, Kolatzki V, Hünerbein K, et al. Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms. Hämostaseologie. 2024;44(05):386-392. doi:10.1055/a-2159-8767
BibTeX
@article{Wille2024,
author = {Wille, Kai and Deventer, Eva and Sadjadian, Parvis and Becker, Tatjana and Kolatzki, Vera and Hünerbein, Karlo and Meixner, Raphael and Jiménez-Muñoz, Marina and Fuchs, Christiane and Griesshammer, Martin},
title = {Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms},
journal = {Hämostaseologie},
year = {2024},
volume = {44},
number = {05},
pages = {386--392},
doi = {10.1055/a-2159-8767}
}
EUVIMED